Tesamorelin

Tesamorelin is a synthetic growth hormone releasing hormone analogue approved in the United States for reducing excess abdominal fat in people with HIV-associated lipodystrophy. That indication is narrow, and the marketing interest in it for general body composition or anti-aging goes well beyond what was studied.

Evidence-first summary of tesamorelin, a growth hormone releasing hormone analogue: its narrow approved indication, human trial evidence, risks and unknowns.

An approved peptide with a deliberately narrow indication - and a lot of off-label interest.

Key takeaways

Why the indication is narrow

Approval followed trials in a specific clinical problem: excess visceral fat in people with HIV-associated lipodystrophy. The benefit-risk judgement regulators made applies to that situation. It does not extend automatically to a healthy adult seeking body composition changes.

Growth hormone axis effects

Stimulating growth hormone release raises IGF-1, which is why monitoring is part of appropriate clinical use. Joint symptoms, fluid retention and glucose intolerance are recognised effects of increased growth hormone signalling.

Off-label interest

Because tesamorelin is approved, it is sometimes presented online as a 'legitimate' anti-aging peptide. Approval for one indication is not evidence for another.

Beiing does not publish dosages, schedules, administration instructions, combinations or sourcing guidance for this or any other compound.

Frequently asked questions

Is tesamorelin approved for weight loss?

No. Its approval concerns excess abdominal fat in HIV-associated lipodystrophy, which is a specific clinical condition.

Is it the same as taking growth hormone?

No. It stimulates the pituitary to release growth hormone rather than supplying growth hormone directly, though downstream effects overlap.

Does it work in healthy adults?

That has not been established in an adequate trial base, and its risks in that group are not well characterised.

Related on Beiing

Sources

  1. FDA - Drug Approvals and Databases - U.S. Food and Drug Administration
  2. PubMed - National Library of Medicine - NIH
  3. ClinicalTrials.gov - U.S. National Library of Medicine

Written by Beiing Editorial Team · Editorially reviewed by Research & Regulatory Review Desk · Published · Last reviewed . Editorial and research review by Beiing writers and researchers. This is not medical or clinical review, and no clinician signs off on our content.

Educational content only - not medical advice. In a crisis, call or text 988 (US) or your local emergency number. See crisis resources.